SG11201704427YA - Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal - Google Patents

Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal

Info

Publication number
SG11201704427YA
SG11201704427YA SG11201704427YA SG11201704427YA SG11201704427YA SG 11201704427Y A SG11201704427Y A SG 11201704427YA SG 11201704427Y A SG11201704427Y A SG 11201704427YA SG 11201704427Y A SG11201704427Y A SG 11201704427YA SG 11201704427Y A SG11201704427Y A SG 11201704427YA
Authority
SG
Singapore
Prior art keywords
polypeptides
amino acid
acid sequence
sequence lacking
modified bacteriophage
Prior art date
Application number
SG11201704427YA
Other languages
English (en)
Inventor
Rajaraman Krishnan
Eva Asp
Ming Proschitsky
Richard Fisher
Francis J Carr
Robert G E Holgate
Timothy D Jones
Original Assignee
Proclara Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proclara Biosciences Inc filed Critical Proclara Biosciences Inc
Publication of SG11201704427YA publication Critical patent/SG11201704427YA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1716Amyloid plaque core protein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00Bacteriophages
    • C12N2795/00011Details
    • C12N2795/14011Details ssDNA Bacteriophages
    • C12N2795/14022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SG11201704427YA 2014-12-03 2015-12-02 Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal SG11201704427YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462087052P 2014-12-03 2014-12-03
PCT/US2015/063476 WO2016090022A1 (en) 2014-12-03 2015-12-02 Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal

Publications (1)

Publication Number Publication Date
SG11201704427YA true SG11201704427YA (en) 2017-06-29

Family

ID=55273507

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201704427YA SG11201704427YA (en) 2014-12-03 2015-12-02 Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal

Country Status (20)

Country Link
US (2) US10722551B2 (https=)
EP (1) EP3227313B1 (https=)
JP (2) JP6730988B2 (https=)
KR (1) KR20170085132A (https=)
CN (1) CN107250154A (https=)
AR (1) AR102890A1 (https=)
AU (1) AU2015358504A1 (https=)
BR (1) BR112017011530A2 (https=)
CA (1) CA2969128A1 (https=)
DK (1) DK3227313T3 (https=)
EA (1) EA201791212A1 (https=)
ES (1) ES2910017T3 (https=)
IL (1) IL252426A0 (https=)
MX (1) MX2017007059A (https=)
PH (1) PH12017501004A1 (https=)
PL (1) PL3227313T3 (https=)
PT (1) PT3227313T (https=)
SG (1) SG11201704427YA (https=)
TW (1) TW201632542A (https=)
WO (1) WO2016090022A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114748605A (zh) 2011-11-29 2022-07-15 普罗克拉拉生物科学股份有限公司 噬菌体基因3蛋白组合物及作为淀粉样蛋白结合剂的用途
CN104870008B (zh) 2012-10-02 2019-10-01 普罗克拉拉生物科学股份有限公司 噬菌体的p3融合蛋白作为淀粉样蛋白结合剂的用途
KR20160010618A (ko) 2013-05-28 2016-01-27 뉴로페이지 파마슈티컬즈, 인크. 감소된 면역원성을 갖는 개질된 박테리오파아지 g3p 아미노산 서열을 포함하는 폴리펩티드
PL3227313T3 (pl) 2014-12-03 2022-05-09 Proclara Biosciences, Inc. Polipeptydy zawierające zmodyfikowaną sekwencję aminokwasową bakteriofaga g3p pozbawioną sygnału glikozylacji
EP3806884B1 (en) * 2018-06-15 2023-08-02 Amyl Therapeutics General amyloid interaction motif (gaim)
CN120641092A (zh) 2022-12-02 2025-09-12 阿尔泽恩股份有限公司 用于用曲米沙特治疗神经变性病症的方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
ATE194384T1 (de) 1989-09-12 2000-07-15 Hoffmann La Roche Tnf-bindende proteine
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
DK0575545T3 (da) 1991-03-15 2003-09-15 Amgen Inc Pegylering af polypeptider
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
DE69334070T2 (de) 1992-05-26 2007-01-04 Immunex Corp., Thousand Oaks Neue zytokine die cd30 binden
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
WO2000034317A2 (en) 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins
US20020052311A1 (en) 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
US8022270B2 (en) 2000-07-31 2011-09-20 Biolex Therapeutics, Inc. Expression of biologically active polypeptides in duckweed
US7189830B2 (en) 2001-02-19 2007-03-13 Merck Patent Gmbh Anti-KSA/IL-2 fusion proteins with reduced immunogenicity
MXPA03008032A (es) 2001-03-08 2003-12-04 Merck Patent Gmbh Factor de estimulacion de colonias de granulocitos- macrofagos modificado con inmunogenicidad reducida.
DE10238846A1 (de) 2002-08-20 2004-03-04 Nemod Immuntherapie Ag Aktive Fusionsproteine und Verfahren zu ihrer Herstellung
EP1853285B1 (en) 2005-02-01 2011-03-16 Ramot at Tel-Aviv University Ltd. Method for treating inflammation associated with amyloid deposits and brain inflammation involving activated microglia
MX2008010612A (es) 2006-02-15 2009-03-20 Ramot At Tel Aviv University Bacteriofago filamentoso que exhibe proteina a como aglutinante de anticuerpos e inmunocomplejos para el suministro hacia el cerebro.
US20090304726A1 (en) 2006-02-15 2009-12-10 Ramot At Tel Aviv University Ltd. Viral display vehicles for treating multiple sclerosis
WO2007109733A2 (en) 2006-03-21 2007-09-27 The Johns Hopkins University Diagnostic and prognostic markers and treatment strategies for multiple sclerosis
WO2007114139A1 (ja) 2006-04-06 2007-10-11 Fumiaki Uchiyama 新規繊維状ファージによるファージディスプレイ
EP2054515B1 (en) 2006-07-21 2012-01-11 Ramot at Tel-Aviv University Ltd. Use of a phage displaying a peptide from an adhesion protein for treating a disease associated with intracellular formation of protein fibrillar inclusions or aggregates
EP2080138A2 (en) 2006-10-11 2009-07-22 Antitope Limited T cell epitope databases
WO2009143470A1 (en) 2008-05-22 2009-11-26 Ramot At Tel Aviv University Ltd. Method for treating disease characterized by plaque
RU2011125971A (ru) 2008-11-24 2012-12-27 Рамот Эт Тель-Авив Юниверсити Лтд. Способ лечения болезни паркинсона
WO2011084714A2 (en) 2009-12-17 2011-07-14 Biogen Idec Ma Inc. STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF
BR112013023040A2 (pt) 2011-03-11 2018-10-23 Univ Ramot bacteriófago filamentoso, composição farmacêutica, e, métodos para reduzir a formação de fibrilas de proteína tau ou para desagregar fibrilas pré-formadas de proteína tau em um paciente, e para tratar uma tauopatia degenerativa.
CN114748605A (zh) 2011-11-29 2022-07-15 普罗克拉拉生物科学股份有限公司 噬菌体基因3蛋白组合物及作为淀粉样蛋白结合剂的用途
CN104870008B (zh) 2012-10-02 2019-10-01 普罗克拉拉生物科学股份有限公司 噬菌体的p3融合蛋白作为淀粉样蛋白结合剂的用途
KR20160010618A (ko) * 2013-05-28 2016-01-27 뉴로페이지 파마슈티컬즈, 인크. 감소된 면역원성을 갖는 개질된 박테리오파아지 g3p 아미노산 서열을 포함하는 폴리펩티드
PL3227313T3 (pl) 2014-12-03 2022-05-09 Proclara Biosciences, Inc. Polipeptydy zawierające zmodyfikowaną sekwencję aminokwasową bakteriofaga g3p pozbawioną sygnału glikozylacji

Also Published As

Publication number Publication date
WO2016090022A9 (en) 2016-08-25
CA2969128A1 (en) 2016-06-09
US20180207231A1 (en) 2018-07-26
AU2015358504A8 (en) 2017-07-13
CN107250154A (zh) 2017-10-13
JP6730988B2 (ja) 2020-07-29
IL252426A0 (en) 2017-07-31
JP2020073610A (ja) 2020-05-14
AR102890A1 (es) 2017-03-29
DK3227313T3 (da) 2022-04-19
AU2015358504A1 (en) 2017-06-29
PH12017501004A1 (en) 2017-12-18
ES2910017T3 (es) 2022-05-11
EP3227313B1 (en) 2022-02-09
TW201632542A (zh) 2016-09-16
WO2016090022A1 (en) 2016-06-09
KR20170085132A (ko) 2017-07-21
US11723951B2 (en) 2023-08-15
PT3227313T (pt) 2022-04-12
JP2017538407A (ja) 2017-12-28
MX2017007059A (es) 2018-05-02
US10722551B2 (en) 2020-07-28
US20210015895A1 (en) 2021-01-21
PL3227313T3 (pl) 2022-05-09
EA201791212A1 (ru) 2018-01-31
WO2016090022A8 (en) 2017-06-22
EP3227313A1 (en) 2017-10-11
BR112017011530A2 (pt) 2018-03-13

Similar Documents

Publication Publication Date Title
IL258041B (en) A new endolysin polypeptide
IL254965B (en) fusion proteins
IL246355B (en) p97–ids fused proteins
GB201417652D0 (en) Improved encoding process using a palette mode
IL251571A0 (en) Variable proteins comprising the cry1da1 amino acid sequence are activated by lepidopteran
IL252426A0 (en) Polypeptides containing a modified bacteriophage g3p amino acid sequence lacking a glycosylation signal
GB201418562D0 (en) Peptides
SG11201509647WA (en) Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity
IL247321B (en) uti chimeric proteins
IL248276A0 (en) Carbohydrate binding proteins
IL252902A0 (en) Amino acid and peptide conjugates and their uses
SG11201606501PA (en) Nanobody-fluorescent protein fusion
GB201401877D0 (en) Peptides
GB2528431B (en) Improved encoding process using a palette mode
HK1249520A1 (en) Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a glycosylation signal
GB201410686D0 (en) Peptides
GB201713537D0 (en) Fusion Polypeptide
GB201420645D0 (en) Peptides
GB201503789D0 (en) Fusion polypeptide
GB201513320D0 (en) Peptides
GB201412731D0 (en) Peptides
GB201409010D0 (en) Peptides
GB201405078D0 (en) Peptides